[Inhibition of the development of thermotolerance by combined treatment with an anticancer drug or benzylidene glucopyranose with the hyperthermia].
Transitional thermotolerance develops during (at below circa 43 degrees C) or after (at above circa 43 degrees C) hyperthermic treatment, increases through the first 6 h, is maintained for circa 24 h and disappears at circa 72 h after the hyperthermia. Therefore, a once every three days modality of hyperthermic treatment is preferred among the clinical institutions where therapeutic hyperthermia is provided. In the present communication, the inhibition of thermotolerance development by combined treatment of anticancer drug or benzylidene glucopyranose with hyperthermia and its related problems are reported.
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D001547:Benzaldehydes / Q000494:pharmacology; D002478:Cells, Cultured; D006224:Cricetinae; D003412:Cricetulus; D004317:Doxorubicin / Q000494:pharmacology; D005947:Glucose / Q000031:analogs & derivatives* / Q000494:pharmacology; D006979:Hyperthermia, Induced; D008937:Mitomycins / Q000494:pharmacology
D000970:Antineoplastic Agents; D001547:Benzaldehydes; D008937:Mitomycins; C013844:benzylidene glucose; D004317:Doxorubicin; D005947:Glucose